Kaposi's sarcoma drug trial halted early
NCT ID NCT01412515
First seen Jun 10, 2026 · Last updated Jun 12, 2026 · Updated 1 time
Summary
This study tested a daily pill called everolimus in 11 people with classic or endemic Kaposi's sarcoma (a type of skin cancer linked to a virus). The goal was to see if the drug could shrink tumors after 6 months. The trial was stopped early, so results are limited. Participants had at least 10 skin lesions or widespread disease, but no serious organ involvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Saint Louis
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.